The Braingaze pipeline covers some of the most common and challenging mental health disorders in children and in adults, as well as the critical need to early detect Mild Cognitive Impairment. Due to the digital nature of our solutions, our pipeline right from the start focuses on actual eficacy and functionality in humans, which enables throughput times that are much shorter than those encountered when validating the usefulness of molecules for medical purposes.
Right from the initial Proof of Concept stage, our clinical validation work is done in close collaboration with recognized leaders in the fields we touch upon. Any validation study we do is subsequently documented and presented for peer review in highly selective scientific journals. Our studies compare our solutions fairly with alternatives and aim for objectively measureable impact - not self-reported improvements which are highly susceptible to study participant bias.
Cognitive and mental disorders, such as ADHD and ASD are a result of abnormal brain functioning. A key structure in cognitive processing is the brainstem, which is located deep in our brain. The brainstem controls a range of tasks, including attention and memory but also directs eye movements. Monitoring carefully a specific eye movement (Cognitive vergence) during a particular task allows detecting cognitive disorders in an objective manner and with high precision.
Alzheimer ́s Disease is a neurodegenerative illness, manifested by progressive cognitive impairment. It results in severe synaptic and neuronal loss. Recently, studies show that the brainstem nucleus locus coeruleus is the first region to develop pathology precursors and is a critical step in the pathogenesis of Alzheimer ́s Disease. Cognitive Vergence and also pupil diameter are closely linked to the functioning of brainstem nuclei including the locus coeruleus. Our and other studies demonstrate that altered responses in these eye metrics reflect dysfunctional levels of the brainstem.